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the analysis. The model’s effectiveness outcome is deﬁned as patients who are success-
fully treated and are alive. Cost-effectiveness is measured as total costs per patient 
with respect to effectiveness for each medication arm. In addition, sensitivity analyses 
were performed to identify cost-effectiveness for different clinical and economic 
assumptions. RESULTS: The analysis shows that 60% of MICA patients were suc-
cessfully treated and survived at the end of study compared to 58% of CASPO 
patients. Furthermore, the costs of a MICA treatment (a37,212) are below the costs 
of a CASPO treatment (a37,720). Therefore, the cost-effectiveness ratio is lower for 
MICA (a62,377) than for CASPO (a65,565). This result also holds for all but one of 
the sensitivity analyses. However, probabilistic sensitivity and subgroup analyses show 
that differences cannot be considered statistically signiﬁcant due to large variance. For 
European patients only, who can be assumed to be a more homogenous group and a 
better approximation of German patients, cost-effectiveness ratio for MICA is 59,406 
a compared to a68,217 for CASPO, the difference being statistically signiﬁcant. 
CONCLUSIONS: This study analyzes the cost-effectiveness of MICA as compared to 
CASPO for the treatment of systemic candida infections in Germany. Both lower costs 
and higher effectiveness of MICA render MICA as more cost-effective than CASPO.
PIN51
COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS 
VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA 
TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO
Soria-Cedillo IF1, Baca-Muro VI2, De la Mora-Chávez T3, Jirash J4, Garcia-Contreras F5
1Research Consulting, Hacienda Ojo de Agua, Mexico, 2Research Consulting, Puebla, Mexico, 
3Instituto Mexicano del Seguro Social, Mexico City, Mexico, 4Novartis Farmaceutica Mexico, 
Mexico D  F., Mexico, 5Instituto Mexicano de Seguro Social, Mexico D.F., Mexico
OBJECTIVES: To establish a cost-effective intravenous antibiotic therapy in the treat-
ment of Infective Endocarditis and Bacteremia. METHODS: A cost-effectiveness study 
was performed considering the expenses and use of resources of Mexican Public Health 
Institutions. The study was based on a decision tree with Bayesian approach deﬁning 
three different health states: clinical success (within short or long hospital stay frame), 
therapeutic failure, and death. The alternatives compared were: a) i.v. Vancomycin 
(VAN) as a ﬁrst-line antibiotic therapy followed by a second-line antibiotic therapy 
in therapeutic failure, or b) i.v. Daptomycin (DAP) as a ﬁrst-line or second-line anti-
biotic therapy. The most recent published data concerning efﬁcacies, length of hospital 
stay and adverse events were included in the study. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of most uncertain variables. 
RESULTS: The use of i.v. Daptomycin as ﬁrst-line antibiotic therapy represents savings 
of US$4,619.00 per patient reaching clinical success (CS) when compared to the use 
of i.v. Vancomycin as ﬁrst-line antibiotic therapy (DAP-VAN: US$21,168.00/CS; 
VAN-2nd line antibiotic: US$25,787.00/CS). A greater proportion of patients are more 
likely to attain clinical success when DAP is used as ﬁrst-line antibiotic therapy (DAP-
VAN: 62%; VAN-2nd line antibiotic: 54%) due to a less frequent development of 
adverse events compared to the use of VAN. The sensitivity analysis varying clinical 
success rates of every evaluated alternative demonstrated the robustness of the base 
study. CONCLUSIONS: Daptomycin is the most cost-effective alternative in the treat-
ment of Infective Endocarditis and Bacteremia when used as ﬁrst-line antibiotic therapy 
since it decreases hospital expenses due to a reduced hospital stay and results in a 
greater proportion of patients reaching clinical success. The use of Vancomycin in 
long term treatments is associated with a higher frequency of adverse events which 
can cause treatment interruption resulting in therapeutic failure.
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OBJECTIVES: To estimate the impact of the use of more detailed direct medical costs 
for the economic evaluations (EEs) of universal vaccinations against rotavirus and 
varicella in Brazil on the incremental cost-effectiveness ratios (ICERs). METHODS: 
Previous published EEs were used as basis and new direct medical costs estimates for 
rotavirus and varicella were developed, with the inclusion of speciﬁc costs of the private 
health care system (HCS) for the two diseases, inclusion of public participation for 
dispensing drugs in the case of rotavirus and inclusion of drugs costs in the public HCS 
in the case of varicella. Cost estimate methods consisted of gross-costing and micro-
costing. Data were obtained from national regulatory agency database (ANS), house-
hold survey (PNAD), private (CBHPM, TUNEP) and public (Ministry of Health) 
reference lists. Direct medical costs were then applied to the previous models, preserv-
ing non-medical direct and indirect costs, all costs in 2004 Reals. ICERs were recalcu-
lated and compared to the original calculations, from the HCS and societal perspective. 
Univariate sensitivity analysis was performed to each cost item and discount rate to 
analyse individual impact on ICER. RESULTS: From the societal perspective, there 
was an estimated disease total cost increase of 16% for rotavirus and 11% for varicella, 
as well as increase of savings with the vaccination of 18% and 16%, respectively. 
ICERs were reduced by 20% for rotavirus (to a292/LYS) and 4% for varicella (to 
a4098/LYS), still below the threshold (3xGDP per capita). Sensitivity analysis indicated 
that EEs of vaccination against rotavirus and varicella were more sensitive to the vac-
cination program cost estimates, especially the vaccine price. CONCLUSIONS: 
Although the more detailed cost estimates reduced the ICERs, the level of cost-effective-
ness of the two vaccination programs remained the same. Sensitivity analysis pointed 
out the relevance of the vaccine cost comparatively to the direct medical costs.
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OBJECTIVES: Standard treatment for hepatitis C is peginterferon (PEG-IFN)  RBV 
with the aim of achieving a sustained-virological-response (SVR), which is widely 
considered to be a cure. Around 50% of patients infected with G1 do not achieve 
an SVR but re-treatment with PEG-IFN  RBV is successful in some, especially in 
those who achieve a complete-early-virological-response (HCV-RNA undetectable 
by week 12 [cEVR]). The objective of this analysis was to determine the cost-effective-
ness of re-treating previous G1-non-responders to PEG-IFN  RBV. METHODS: 
A published Markov-model compared three strategies: PEG-IFNA2a  RBV, for 72 
weeks (A), 48 weeks (B) or no treatment (C). Efﬁcacy data for (A) and (B) were taken 
from the REPEAT study, where a difﬁcult-to-treat population of G1-patients with 
previous non-response to PEG-IFN/RBV was investigated. Rates of cEVR were 15% 
for (A) and 9% for (B); SVR rates: 13% for (A) and 7% for (B); rates for (C) assumed 
to be zero. Patients not achieving a cEVR were assumed to discontinue treatment. 
A UK health care payor perspective was adopted. Drug and other costs were taken 
from published sources. A lifetime-horizon was chosen. Incremental-cost-effectiveness-
ratios were expressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs 
were discounted at 3.5% p.a. Sensitivity-analyses were performed. RESULTS: 
The analysis showed that an additional SVR prevented future costs and increased 
quality-adjusted-life-expectancy. Although (A) caused the highest overall drug costs, 
total costs were only £606 higher compared to (B) and £1949 compared to (C), 
reﬂecting the higher SVR rates and the substantial medical costs for patients without 
an SVR. The ICER of (A) vs. (B) was estimated at £2,012/QALY and £2,988/QALY 
for (A) vs. (C). CONCLUSIONS: Re-treatment with PEG-IFNA2a  RBV for 72 weeks 
is a highly cost-effective treatment option for patients not responding to previous 
treatment with PEG-IFN  RBV, regardless of comparator, due to reduction of 
the high medical costs associated with progressive liver disease and the associated 
QALY gains.
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OBJECTIVES: The 7-valent pneumococcal conjugate vaccine (PCV7) and 23-valent 
pneumococcal polysaccharide vaccine (PPV23) are currently recommended for child-
hood and adult vaccination respectively in the UK. A 13-valent pneumococcal conju-
gate vaccine (PCV13) is currently being reviewed by regulatory authorities for use in 
infants and young children, and a clinical development plan for adults is ongoing. 
This study assessed cost-effectiveness of PCV13 compared to the current vaccination 
strategy and to PCV7 given to children alone. METHODS: A steady state, static 
cohort model was constructed comparing PCV13 vaccination of the birth cohort and 
of 65-year old adults with the current strategy and with PCV7 in children alone. The 
model con sidered the incidence and subsequent costs of four infections: pneumococcal 
meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media 
(AOM). Vaccination was assumed to have effects on vaccinated individuals and to 
impact unvaccinated individuals as a result of herd immunity. The number of cases 
and subsequent costs that would occur were estimated in the different scenarios. Sen-
sitivity analysis considered incidence, mortality rates, vaccine efﬁcacy, serotype cover, 
costs, discount rate, uptake and herd immunity. RESULTS: The model estimated that, 
compared to the current strategy (and compared to PCV7 alone), PCV13 would reduce 
the annual incidence of bacteraemia and meningitis by 1176 (1303) cases, prevent 35 
(40) deaths, increase life years by 619 (666), increase QALYs by 694 (731) and reduce 
medical costs by £2.9m (£11.1m). Results are sensitive to vaccine effects against 
pneumonia and the disease incidence in non-vaccinated individuals. CONCLUSIONS: 
Paediatric and adult PCV13 vaccination in the UK was estimated to reduce the burden 
of pneumococcal disease and save costs compared with either the current vaccination 
strategy or a paediatric PCV7 only strategy. Final cost-effectiveness will depend on 
the emergence of herd immunity beneﬁts in the UK, impact on pneumonia, vaccine 
schedule and price.
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OBJECTIVES: To determine the cost-effectiveness of the protocol of the international          
‘Surviving Sepsis Campaign’ (SSC) for the treatment of severe sepsis in Spain after the 
implementation of a multicentre educational program compared with the conventional 
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care of severe sepsis. METHODS: Observational prospective before and after study      
in 59 medical-surgical intensive care units located throughout Spain. A total of 854 
patients were enrolled in the pre-educational program cohort (usual or standard care    
of severe sepsis, November-December 2005) and 1465 patients during the post-      
 educational program (SSC protocol care of severe sepsis, March-June 2006). The 
educational program aimed to increase the adherence to the SSC protocol. The SSC 
protocol included pharmacological (antibiotics, ﬂuids, steroids and drotrecogina 
alfa (activated)) and medical (early-goal directed therapy, tight glucose control and 
lung protective strategy) interventions. Clinical (hospital mortality) and economical 
(health care resource and treatment costs) outcomes were recorded. Health care system 
perspective was used for costs. Incremental cost-effectiveness ratios (ICERs) and 
incremental cost-utility ratios (ICURs) were used as primary outcomes. ICERs and 
ICURs were estimated by using multivariable regression models and its variability 
addressed by using bootstrapping. RESULTS: Patients in the SSC protocol care cohort       
had a lower risk of hospital mortality (44.0% vs. 39.7%, P  0.04). However, the 
SSC protocol care resulted in a mean increase in cost of a1800 per patient, largely 
driven by increased length of stay. Mean life years gained (LYG) and quality-adjusted 
life years (QALYs) were higher in the SSC protocol care cohort: 0.7 years and 
0.5 QALYs, respectively. The adjusted ICER of the SSC protocol was a2556.9 per 
LYG and the adjusted ICUR was a3579.6 per QALY. Ninety percent of the bootstrap 
replications were below the threshold of a30,000 per LYG. CONCLUSIONS: The 
SSC protocol seems to be a cost–effectiveness option for treating severe sepsis in 
Spain.
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OBJECTIVES: To assess the cost-effectiveness of atazanavir/r vs. lopinavir/r in treat-
ment-naïve HIV patients in Spain. METHODS: A life-time Markov-cohort model 
was created with the following health states 1st line, 2nd line and salvage therapy. 
The cycle length was one year; patients could switch treatment due to adverse events, 
lack of efﬁcacy or non-compliance. Those discontinuing 1st line treatment due lack 
of efﬁcacy switched to darunavir/r. Those that discontinued 1st line due to adverse 
events or non-compliance switched to efavirenz/emtricitabine/tenofovir. Everyone 
discontinuing 2nd line was given a salvage therapy. Patients were at risk of developing 
a cardiovascular event or to die in each state. Drug speciﬁc safety and efﬁcacy inputs 
were taken from the 48 week CASTLE trial, risk of cardiovascular events were 
estimated with Framingham equation and risk of death was from Spanish life-tables 
and literature. The analysis was done from a societal perspective; outcomes were 
total costs and Quality-Adjusted Life Years after life-time. Robustness was assessed 
by uni- and multivariate sensitivity analyses. Recent 96-week trial efﬁcacy and safety 
data from the CASTLE was used as a scenario analysis. RESULTS: The model fore-
casted a difference of 0.20 [0.11 to 0.32] QALYs after life-time and a reduction in 
total costs of a7,000 [a28,888 to a12,491]. Probabilistic sensitivity analyses showed 
that atazanavir/r has a 23.5% and a 76.5% probability to be in the NE and SE 
quadrant of cost-effectiveness plane. Univariate sensitivity analysis showed that results 
were most sensitive to changes in probabilities of switching treatment. In the scenario 
analysis, a QALY gain of 0.21 was estimated and total costs were estimated to 
be a4500 higher for atazanavir/r. CONCLUSIONS: This analysis suggests that ata-
zanavir/r has a favorable cost-effectiveness ratio for treatment naïve HIV patients 
in Spain.
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OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7, Prevenar*) is 
 currently recommended for childhood vaccination in the UK. A 10-valent vaccine 
(PCV10, Synﬂorix, GSK) is licensed and a 13-valent vaccine (PCV13, Wyeth) is cur-
rently being reviewed by regulatory authorities. This study estimated the cost effective-
ness of PCV13 and PCV10 compared to PCV7 for childhood vaccination in the UK. 
METHODS: A steady state, static cohort model was constructed comparing the 
incremental beneﬁt of PCV13 compared to PCV7 and PCV10 compared to PCV7 for 
vaccination of the entire birth cohort. In children, the model considered the incidence 
and subsequent costs of four disease states: pneumococcal meningitis; pneumococcal 
bacteraemia; all cause pneumonia and acute otitis media (AOM). In adults the model 
considered invasive pneumococcal disease (IPD) and all cause pneumonia, exploring 
the potential impact of herd immunity. Sensitivity analyses were conducted on inci-
dence, mortality rates, vaccine efﬁcacy, serotype coverage and costs, discount rate, 
uptake and non-vaccine serotype prevalence. RESULTS: The model estimated that, in 
addition to PCV7, PCV13 (PCV10) would annually reduce the incidence of IPD by 
888 (573) cases, prevent 23 (16) deaths, increase the number of life years gained by 
509 (343), increase QALYs gained by 611 (375) and reduce medical costs by £5.2m 
(£3.3m). The beneﬁts of the new vaccines are sensitive to efﬁcacy and the magnitude 
and pattern of herd immunity that emerges. CONCLUSIONS: Our analysis found 
that PCV13 vaccination in the UK will be more effective than PCV10 in reducing the 
burden of pneumococcal disease when compared to PCV7 and will further reduce 
cost. Final cost-effectiveness will depend on the emergence of herd immunity beneﬁts 
in the UK, the impact on AOM and pneumonia, the vaccination schedule deployed 
and price of PCV13 and PCV10.
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OBJECTIVES: To determine whether, from the Swedish health care payer perspective 
etravirine is cost-effective when added to a standard highly active antiretroviral treat-
ment (HAART) in multi-drug resistant HIV-1 infected adults. METHODS: Etravirine 
added to a standard regimen including darunavir/r, an optimized background regimen 
(OBR) of nucleoside reverse transcriptase inhibitors (NRTIs) and optionally enfu-
virtide was compared to the same standard regimen alone. The target population 
consisted of HIV-1-infected pretreated patients with resistance to non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and q3 protease inhibitor (PI) mutations. 
Cost-effectiveness, expressed as cost per quality-adjusted life year (QALY) gained, was 
calculated using a lifetime Markov model. The model predicted patient ﬂow through 
six health states representing CD4 T-cell count ranges (500, 351–500, 201–350, 
101–200, 51–100 and 0–50 cells/mm3), and one absorbing ‘death’ state. After treat- 
ment failure, a switch to a raltegravir regimen was assumed. Transition probabilities      
describing patient ﬂow through the model were obtained from immunologic response 
rates per virologic response category observed in the DUET trials for etravirine and 
placebo and reported in phase III trials for raltegravir. All-cause mortality was   
obtained from Swedish statistics. HIV-related mortality, utilities and non-ARV costs 
associated with each CD4 T-cell count range were obtained from literature. Antiret-
roviral (ARV) drug use reﬂected that observed in the clinical trials. Outcomes and            
costs expressed in 2008 Swedish Kronor (SEK) were discounted at 3%. The impact 
of parameter uncertainty was explored in one-way as well as probabilistic sensitivity 
analysis. Variability analyses explored different model assumptions. RESULTS: The 
analysis predicted a gain in discounted QALYs of 0.461 and an incremental cost per 
QALY of SEK362,583, ranging from 240,074SEK/QALY to 474,935SEK/QALY in 
sensitivity and variability analyses. CONCLUSIONS: The results suggest etravirine to 
be cost-effective in Sweden when added to a standard multi-drug regimen in pretreated 
HIV patients with evidence of NNRTI and PI resistance.
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OBJECTIVES: Outpatient parenteral antimicrobial therapy (OPAT) with carbapenem 
for bacteraemia caused by extended-spectrum beta-lactamase (ESBL)-producing bac-
teria may potentially be cost-saving. Yet in Hong Kong, China and many southeast 
Asia regions, patients requiring intravenous antimicrobial therapy are usually treated 
in an in-patient setting. In the present study, we analyzed the cost of inpatient versus 
outpatient carbapenem treatment for ESBL bacteraemia. METHODS: Economic out-
comes of two antimicrobial strategies were simulated by a decision tree: 1) inpatient 
carbapenem treatment; 2) outpatient group (initially inpatient carbapenem treatment 
followed by ertapenem OPAT). Clinical inputs were estimated from literature and cost 
analysis was conducted from Hong Kong public health care provider’s perspective. 
Robustness of model was examined by sensitivity analysis. RESULTS: The results 
showed that outpatient group (US$12,008) was less costly than the inpatient group 
(US$15,446) (USD1  HKD7.8) by 22% in base-case analysis. The model was robust 
to variation of all variables in one-way sensitivity analysis. In Monte Carlo stimula-
tions, cost of outpatient group (US$13,153 o 2,064) was signiﬁcantly lower than the      
inpatient group (US$15,650 o 1,602) 98.6% of the time by a mean difference of          
US$2,497 (95% CI  US$2,469–2,525) (p  0.0001). CONCLUSIONS: Initial inpa-
tient carbapenem treatment followed by OPAT appears to be less costly than an 
inpatient treatment course for ESBL bacteraemia from the perspective of Hong Kong 
public health care providers.
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 
peginterferon alfa-2a compared to entecavir for the treatment of HBeAg-positive 
chronic hepatitis B in China. METHODS: A Markov health-state model was designed 
to estimate the direct medical costs and outcomes (life year gained and QALY) of 
treating HBeAg-positive chronic hepatitis B in China. The model included 11 health 
states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg loss, CHB with 
resistance, Flare due to resistance, Compensated cirrhosis, Decompensated cirrhosis, 
Hepatocellular carcinoma, Liver transplant, Post-liver transplant and death. The evo-
lution of a cohort of HBeAg-positive CHB patients was simulated along 80 years with 
yearly cycles. The clinical and quality of life data were obtained from published litera-
ture. From the perspective of Chinese health insurance system, cost data was calculated 
